Sarepta Therapeutics (SRPT)

Executive Summary

Sarepta Therapeutics is a precision genetic medicine leader focused on rare neuromuscular and central nervous system diseases, with a strong commercial portfolio of FDA-approved therapies for Duchenne muscular dystrophy (DMD), including Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), and the gene therapy Elevidys (delandistrogene moxeparvovec). The company’s RNA-targeted and gene therapy platforms address underlying genetic causes, positioning it as a frontrunner in DMD treatment. Despite challenges from competitors and reimbursement dynamics, Sarepta’s approved products generate recurring revenue and support ongoing R&D. Key pipeline catalysts include the potential label expansion of Elevidys to older DMD patients, which could significantly broaden the addressable market. The ongoing Phase 3 trial of eteplirsen (NCT03992430) is expected to report data by late 2026, potentially reinforcing its clinical utility. Additionally, next-generation exon-skipping candidates like SRP-5051 may advance, offering improved muscle targeting. With a robust balance sheet and a focused strategy, Sarepta is well-positioned to maintain its leadership in DMD and expand into other rare diseases.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Elevidys label expansion to include older DMD patients (ambulatory and non-ambulatory)70% success
• Q4 2026Phase 3 data readout for eteplirsen (NCT03992430) in DMD60% success
• H2 2026Clinical update on SRP-5051 (next-generation PPMO exon skipping) Phase 2 initiation or early data50% success